Rhythm Pharmaceuticals Q3 EPS $(0.82) Misses $(0.73) Estimate, Sales $51.298M Beat $50.705M Estimate

Author: Benzinga Newsdesk | November 04, 2025 07:00am
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported quarterly losses of $(0.82) per share which missed the analyst consensus estimate of $(0.73) by 12.79 percent. This is a 12.33 percent decrease over losses of $(0.73) per share from the same period last year. The company reported quarterly sales of $51.298 million which beat the analyst consensus estimate of $50.705 million by 1.17 percent. This is a 54.28 percent increase over sales of $33.251 million the same period last year.

Posted In: RYTM